Press releases
- Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
- Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
- Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
- Sobi publishes Annual and sustainability report for 2023
- Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024
More ▼
Key statistics
On Friday, Swedish Orphan Biovitrum AB (publ) (B6E0:FRA) closed at 11.50, -10.16% below its 52-week high of 12.80, set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.50 |
---|---|
High | 11.50 |
Low | 11.50 |
Bid | 11.50 |
Offer | 12.60 |
Previous close | 11.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 03 2024 07:06 BST.
More ▼